Edit
Valeritas
https://www.valeritas.com/Last activity: 11.03.2021
Active - Reference to Zealand Pharma
Developing non-electrical basal and bolus drug delivery technologies and devices for large and small molecules. The first product is a basal-bolus insulin pump for the Type II Diabetes market.
Location: United States, New Jersey, Parsippany-Troy Hills
Total raised: $250M
Investors 5
| Date | Name | Website |
| - | Phoenix Ve... | phoenix-vp... |
| - | CRG | crglp.com |
| - | Kaiser Per... | kpventures... |
| 11.03.2021 | Abingworth... | abingworth... |
| - | Agate Medi... | agate-inve... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.06.2013 | - | $100M | - |
| 12.09.2011 | Series C | $150M | - |
Mentions in press and media 15
| Date | Title | Description |
| 26.03.2015 | Diabetes: Valeritas delays $75m IPO | Valeritas today postponed its planned initial public offering, which at the midpoint was slated to fetch $75 million for its V-Go basal insulin delivery system for Type II diabetes, Renaissance Capital reported. Earlier this month Valeritas... |
| 12.03.2015 | Valeritas sets terms for $75m IPO | Medtech Wall Street news for the week of March 9, 2015 | Diabetes: Valeritas sets terms for $75m IPO March 10, 2015 by Brad Perriello Valeritas yesterday set the terms for its forthcoming initial public offering, saying it plans to put up 5 million shares at $14 to $16 each. At the midpoint of th... |
| 10.03.2015 | Diabetes: Valeritas sets terms for $75m IPO | Valeritas yesterday set the terms for its forthcoming initial public offering, saying it plans to put up 5 million shares at $14 to $16 each. At the midpoint of the range, the IPO would fetch $75 million for Bridgewater, N.J.-based Valerita... |
| 13.02.2015 | Diabetes: Valeritas registers $90m IPO | Valeritas yesterday registered for an initial public offering worth up to $90 million for its V-Go insulin delivery system. Bridgewater, N.J.-based Valeritas said it plans to list on the NASDAQ exchange under the "VLRX" symbol. Th... |
| 07.07.2014 | Type 2 insulin pump maker Valeritas raising large equity round | Valeritas raised $100 million in structured debt financing in June 2013 to commercialize the V-Go, building on the $150 million it raised in Series C venture capital in 2011. The company will not yet comment on the latest fund-raise, a spok... |
| 16.10.2013 | Straight Talk About Diabetes: More Tools Needed | Preventative measures should actually include bariatric procedures, he added, noting, “The risk reduction (following bariatric procedures) is anywhere from 22 percent to 70 percent.” Surgery ‘Powerful Tool’ Against Diabetes But Dr. Herman, ... |
| 07.06.2013 | Valeritas Closes $100M Debt Financing with Capital Royalty | Valeritas, Bridgewater, N.J.-based insulin delivery device, closed a $100m structured debt financing with Capital Royalty L.P. The company intends to use the funds to further support the US commercialization of the V-Go, its insulin deliver... |
| 04.06.2013 | Diabetes: Valeritas lands $100M fund for insulin delivery system | Diabetes devices maker Valeritas announced today that it closed a structured debt financing with $100 million to support commercial efforts of its V-Go insulin delivery system. The new funding adds to Valeritas’ previously raised $150 milli... |
| 09.07.2012 | B-to-c diabetes patient engagement company adds b-to-b capability | As various healthcare stakeholders look for ways to engage patients in a bid to keep them healthy and reduce overall costs, it is creating opportunities for companies who already have a connection with consumers. One such company is dLife, ... |
| 12.09.2011 | Valeritas Raises $150m in Series C financing. | Valeritas Inc., a Bridgewater, N.J.-based developer of drug delivery solutions for diabetes, has raised $150m in Series C financing. The round was led by Welsh, Carson, Anderson & Stowe, which assumes a controlling interest in Valeritas... |
Show more